Results of serogroup B meningococcal vaccines in phase II/III trials
| Vaccine developer | Vaccine constituents | Immunogenicity | Efficacy | Reference |
|---|---|---|---|---|
| Meningococci are classically classified by: (1) serogroup (the biochemical nature of the capsular polysaccharide: A, B, C, Y, W135); (2) serotype (the antigenic type of a surface protein called PorB); and (3) serosubtype (the antigenic type of a surface protein called PorA). Hence strain B:15:P1.7,16 is serogroup B, subtype 15, sersubtype P1.7,16. | ||||
| Connaught Laboratories Inc., USA | Aluminium hydroxide adsorbed serogroup B OMP (B:4:P1.3) + C polysaccharide | Induction of bactericidal antibody but poor responses in young children (<4 years) | 70% efficacy in older children in Chile. No protection <4 years of age | 26 |
| Finlay Institute, Cuba | Aluminium hydroxide adsorbed OMV from CU385 (B:4:P1,15) plus C polysaccharide | Variable immunogenicity. Good response in Cuban teenagers and children in Chile against the homologous strain. Poor immunogenicity in Brazilian children and Icelandic teenagers and limited cross immunogenicity to non-vaccine meningococci | 83% efficacy in Cuban teenagers; 70% efficacy in children >4 years in Brazil; non-protective in children <4 years of age in Brazil | 24, 32–34, 54 |
| NIPH, Norway | Aluminium hydroxide adsorbed OMV from 44/76 (B:15:P1.7,16) | Immunogenic in Norwegian teenagers, Chilean infants and children, and Icelandic teenagers, but limited cross protection to non-vaccine serotypes | 57% in Norwegian teenagers | 29, 33, 55 |
| RIVM, Netherlands | Aluminium phosphate adsorbed combination of 2 different OMVs expressing 6 PorA proteins (P1.7,16; P1.5c,10; P1.5,2; P1.7h,4; P1.19,15; P1.12,13) | Immunogenic in British infants, Dutch toddlers, and Dutch school children but the 6 antigens showed unequal immunogenicity after 3 doses (16–100% response) | Not available | 30, 35 |
| RIVM, Netherlands | Aluminium hydroxide or aluminium phosphate adsorbed OMVs expressing one PorA protein (P1.7h,4) | Immunogenic in Dutch toddlers (55–80% response). Response dependent on adjuvant used | Not available | 56 |